Contraindicated (one)bortezomib will increase the level or outcome of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Potent or moderate CYP2C19 inhibitors could increase mavacamten systemic exposure, resulting in heart failure resulting from systolic dysfunction. To lower the risk of dizziness and lightheadedness, rise up slowly and gradually when rising https://rhosinhydrochloride44320.newsbloger.com/27276078/everything-about-cp-866087